Mobile

A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects with Diabetic Neuropathic Pain

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-001139-71

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare the analgesic efficacy and the safety of ABT-894 (1 mg, 2 mg, or 4 mg capsules) administered twice daily (BID) to placebo in the treatment of diabetic neuropathic pain (DNP). Duloxetine 60 mg administered once daily (QD) will be assessed for assay sensitivity.

Critère d'inclusion

  • Diabetic Neuropathic Pain

Liens